ImmunityBio, Inc. (IBRX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1 | 1 | 0 | 1 | 15 | 113 | 166 | 226 |
| Operating profit | $m | -256 | -252 | ||||||
| Net profit | $m | -222 | -347 | -417 | -583 | -414 | -351 | -992 | -879 |
| EPS reported | $ | -0.38 | -0.97 | ||||||
| Operating cashflow per share | $ | -0.33 | -0.34 | ||||||
| Capex per share | $ | 0.00 | 0.01 | ||||||
| FCF per share | $ | -0.34 | -0.35 | ||||||
| Free cash flow | $m | -309 | -366 | ||||||
| Net debt | $m | 602 | 417 | ||||||
| Book value equity | $m | -500 | -1,047 | ||||||
| Book value per share | $ | -0.54 | -1.00 | ||||||
| Number of shares | m | 919.86 | 1,050.07 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -3.65 | -1.74 | ||||||
| P/S LTM | x | 16.08 | 10.99 | ||||||
| P/FCF LTM | x | -5.90 | -4.98 | ||||||
| EV/EBITDA LTM | x | -11.68 | -2.94 | ||||||
| EV/Sales LTM | x | 23.05 | 52.27 | ||||||
| Earnings Yield LTM | % | -19.29% | -12.48% | ||||||
| FCF Yield | % | -16.95% | -20.07% | ||||||
| Quality | |||||||||
| ROE | % | +70.34% | +134.99% | ||||||
| ROIC | % | -56.95% | -45.01% | ||||||
| Operating margin | % | -2.26% | -1.52% | ||||||
| Gross margin | % | +99.34% | +94.63% | ||||||
| FCF/Sales | % | -272.56% | -220.53% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +668.31% | +1024.4% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.35 | -0.45 | ||||||
| Net Debt/EBITDA | x | -3.53 | -0.83 | ||||||
| EBIT/Net interest | x | -2.28 | -3.02 | ||||||
| Net debt/market cap | % | +46.36% | +9.77% | ||||||
| Net debt/Equity | x | -1.20 | -0.40 | ||||||
| Gross debt/equity | x | -1.76 | -0.78 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free